

Index

A

ACE inhibitors, 78

Adolescence

age range, 70–71

alcohol consumption (*see*
Alcohol consumption)

body art

awareness, 96–97

definition, 94–95

prevalence and risks, 95

changes occurring, 69–70

drug use

cannabis, 91

and diabetes, 88–89

discussing issues, 93

DKA, 89–90

ecstasy and ketamine, 90

festivals and, 94

illegal and legal highs, 88

legal highs, 91, 92

specific events, 91–93

psychological and behavioral

changes, 70–71

sex

body issues, 79

common concerns, 74–75

consultation questions,
80–81

contraception choice, 75–76

diabetes impacts on, 74

factors influencing, 72–73

healthy pregnancies
(*see* Pregnancy and
diabetes)

hypoglycemia and sexual
dysfunction, 80

passing it on risks, 76–77

prevalence, 72

risk-taking tips, 73

smoking

and diabetes, 85–86

European schools survey
project, 85

prevention and cessation,
86–87

specific questions and
advice, 87–88

Alcohol consumption

binge drinking, 82–83

and diabetes, 83–84

European schools survey
project, 82

specific questions and advice,
84–85

American Diabetes

Association, 5

Anxiety disorders, 53

Ask, tell, discuss technique, 160

Autonomous motivation,

145–146

B

- BDI. *See* Beck depression inventory (BDI)
 Beck depression inventory (BDI), 15
 Behavior change. *See* Health behavior change support
 Body art
 awareness, 96–97
 definition, 94–95
 prevalence and risks, 95
 Buddying system, 113, 118

C

- Cannabis, 88, 91
 CBT. *See* Cognitive behavioral therapy (CBT)
 CDT. *See* Clock-drawing test (CDT)
 CEMACH. *See* Confidential enquiry into maternal and child health (CEMACH)
 Center for Epidemiology Studies Depression (CES-D), 15
 CES-D. *See* Center for Epidemiology Studies Depression (CES-D)
 CGMS. *See* Continuous glucose monitoring system (CGMS)
 Charlson index, 119
 Clock-drawing test (CDT), 124
 Cognitive behavioral therapy (CBT), 15, 62
 Cognitive dysfunction, 124–125
 Commonsense model, 138
 Comorbid depression, 12
 Comorbidity
 aspects and measures, 119
 cardiovascular disease and, 120
 clinical presentation, 121–122

definition, 118

importance, 118–119

Confidence ruler, 161

Confidential enquiry into maternal and child health (CEMACH), 112

Contemplation stage, 152

Continuous glucose monitoring system (CGMS), 28

Continuous subcutaneous insulin infusion (CSII), 28

Contraception, 75–76

Coronary heart disease, 86

CSII. *See* Continuous subcutaneous insulin infusion (CSII)

D

DAFNE. *See* Dose adjustment for normal eating (DAFNE)

Decision balance tools, 161

Dementia, 124

Depression and diabetes

 burnout, 13–14

 causes, 12–13

 financial costs, 14–15

 relationship, 12

 screening and treatment, 15–17

 symptoms, 11, 12

 WHO definition, 11

Diabetes and special groups

 comorbidity

 aspects and measures, 119

 cardiovascular disease and, 120

 clinical presentation, 121–122

 definition, 118

 importance, 118–119

 minority ethnic groups

 cultural difference, 111

 depression, 105

 PHQ-9, 107–109

- quality and outcomes
 - framework, 107
 - screening tools, 105–106
 - type 2, 104–105
 - WHO-5, 108, 110
 - older people
 - care implications, 123
 - cognitive dysfunction, 124–125
 - depression excluding evaluation, 126–127
 - treatment strategy, 123–124
 - pregnancy (*see* Pregnancy and diabetes)
 - psychological consequences
 - in, 104
- Diabetes, impacts. *See* Resilience and positive outcomes, diabetes
- Diabetes, patient's perspective
 - childhood and, 23–24
 - complications, 44
 - control taking, 40–42
 - diagnosis
 - diet restrictions, 27
 - genetic predisposition, 26–27
 - hypoglycemia, 25
 - insulin injections, 25–26
 - symptoms, 24
 - hyperglycemia and hypoglycemia, 42–43
 - insulin pump
 - bluetooth technology, 29
 - CGMS, 28–29
 - CSII, 28
 - DAFNE course, 30
 - positive and negative experiences
 - diabetic ketoacidosis, 31–32
 - hypoglycemic episodes, 33–34
 - kidney defect, 30
 - spare consumables, 35
 - psychological
 - complications, 45
 - self-consciousness, 43–44
 - stress, 35–36
 - type 1 diabetes
 - assertiveness factors and management, 38
 - emotions, 40
 - symptoms and diagnosis, 37–38
 - weight increase, 39
- Diabetes, psychological burden
 - burden, 8
 - cost of, 4–5
 - daily self-management and, 8–9
 - definition, 1
 - and depression
 - burnout, 13–14
 - causes, 12–13
 - financial costs, 14–15
 - relationship, 12
 - screening and treatment, 15–17
 - symptoms, 11, 12
 - WHO definition, 11
 - diagnosis
 - type 1, 5–6
 - type 2, 6–7
 - healthcare professionals
 - and, 3–4
 - new tasks, 3
 - practice implications, 18
 - prevalence, 2
 - social relationships impacts
 - alcohol consumption, 10
 - family members, 9–10
 - management, 11
- Diabetes-related distress, 56
- Diabetes specialist nurse (DSN), 28
- Diabetic ketoacidosis (DKA), 31, 89–90
- Diabulimia, 75
- DKA. *See* Diabetic ketoacidosis (DKA)

Dose adjustment for normal eating (DAFNE), 30

Drug use, adolescence

cannabis, 91

and diabetes, 88–89

discussing issues, 93

DKA, 89–90

ecstasy and ketamine, 90

festivals and, 94

illegal and legal highs, 88

legal highs, 91, 92

specific events, 91–93

DSN. *See* Diabetes specialist nurse (DSN)

E

Ecstasy, 90

EDWPOP. *See* European

Diabetes Working

Party for Older People

(EDWPOP)

Effective communication and diabetes

approaches, 152–153

beliefs and

behavior support, 140

clinical presentations,

138–139

commonsense model, 138

change/transtheoretical

model, 152

control recognition

empowerment principles,

141

perception, 140–141

realization and

complications, 142

culture clashes, 136

key aspect, 135

motivational interviewing,

151–152

power and limitations

recognition, 143–144

reflection moment, 137

tips and tools

draw/write/explore,

148–149

issues and consultation, 150

silence management and

open discovery

questions, 149

small things focus, 148

time and, 151

unleashed power recognition

autonomous

motivation, 145

helplessness and failure,

144–145

rewarding effort, 147–148

SDT, 145–146

Elicit-provide- elicit (e-p-e)

technique, 160

Emergent adulthood, 69

Emotional support, 162

Empowerment model, 116–117,

141–142

European Diabetes Working

Party for Older People

(EDWPOP), 125

European schools survey project

alcohol consumption, 82

smoking, 85

F

Facial morphing techniques, 86

Family cohesion, 55

Frailty, 120

G

GDM. *See* Gestational diabetes

(GDM)

Gestational diabetes (GDM),

112–114

Guided self-determination, 145

H

HADS. *See* Hospital anxiety and

depression scale

(HADS)

HBSC. *See* Health behaviour in

school-aged children

(HBSC)

- Health behavior change support
 act deciding, 162–163
 action planning, 163–164
 motivation exploring and
 enhancing, 160–161
 note keeping, 167–168
 patient-centered communica-
 tion style, 157
 process model, 158
 process understanding,
 159–160
 resources using, 167
 self-monitoring and reviewing
 progress, 164–165
 setback managing, 165–166
 skills updating, 168
 social support engaging,
 161–162
 techniques used, 159
 work sharing, 166
- Health behaviour in school-aged
 children (HBSC), 72
- Healthcare professionals (HCPs)
 and diabetes, 141. *See also* Effective commu-
 nication and diabetes
- Hospital anxiety and depression
 scale (HADS), 16
- Hyperglycemia, 1, 6, 34, 43, 90
- Hypoglycemia, 32, 34, 57–58, 80,
 84, 125
- I**
- IDOP. *See* Institute of Diabetes
 for Older People
 (IDOP)
- IFG. *See* Impaired fasting
 glycemia (IFG)
- IF-THEN plan, 164
- IGT. *See* Impaired glucose
 tolerance (IGT)
- Illness perceptions model, 138
- Impaired fasting glycemia
 (IFG), 5
- Impaired glucose tolerance
 (IGT), 5
- Informational support, 162
- Institute of Diabetes for Older
 People (IDOP), 125
- Insulin injections, 6, 25, 26, 37,
 48, 54
- Insulin omission, 53
- Insulin pens, 26, 35
- Insulin pump
 bluetooth technology, 29
 CGMS, 28–29
 CSII, 28
 DAFNE course, 30
- K**
- Ketamine, 90
- M**
- MDIs. *See* Multiple daily
 injections (MDIs)
- Metabolic syndrome, 120
- Mini mental state examination
 (MMSE), 124
- Minority ethnic groups and
 diabetes
 cultural difference, 111
 depression, 105
 PHQ-9, 107–109
 quality and outcomes
 framework, 107
 screening tools, 105–106
 type 2, 104–105
 WHO-5, 108, 110
- MMSE. *See* Mini mental state
 examination
 (MMSE)
- Motivational interviewing (MI),
 151–152, 161
- Multiple daily injections
 (MDIs), 27
- N**
- National Institute of Health and
 Clinical Excellence
 (NICE), 16, 106
- National Service Framework for
 Diabetes, 9, 115

Neuropsychological
 assessment, 55
 NHANES III. *See* Third National
 Health and Nutrition
 Examination Survey
 (NHANES III)
 NICE. *See* National Institute of
 Health and Clinical
 Excellence (NICE)
 NovoRapid, 27

P

Patient health questionnaire
 (PHQ-9), 16, 107–108
 Pedometers, 164
 PHQ-9. *See* Patient health
 questionnaire
 (PHQ-9)
 Polycystic ovarian syndrome,
 77, 78
 Positive coping strategies, 60–61
 Preconception glycaemic
 control, 78
 Precontemplation, 152
 Pregnancy and diabetes
 aim of, 111
 CEMACH, 112–113
 GDM, 112
 NICE, 113–114
 preconception and postnatal
 care, 115
 psychological impacts, 114
 recommendations, 117–118
 teratogenic drugs, 78–79
 two models, 116–117
 type 1, 77
 type 2, 77–78
 Psychological burden, diabetes.
See Diabetes,
 psychological burden

Q

Quality and outcomes
 framework, 107

R

Relapse management
 techniques, 165
 Resilience and positive
 outcomes, diabetes
 appraisals, 48–49
 emotional well-being
 depression, 52
 insulin omission and
 anxiety disorders, 53
 phobia, 54
 family factors influencing
 adjustment
 clinical presentation,
 56–57
 cohesion, 55–56
 diabetes-related
 distress, 56
 fear of hypoglycemia,
 57–58
 maternal depression and
 anxiety, 58–59
 practice tips, 60
 immediate and long-term
 implications, 47–48
 initial diagnosis, 49
 positive coping strategies,
 60–61
 psychologist support, 50
 school problems, 54–55
 solution-focused approach, 51
 treatment approaches
 collaborative working
 practices development,
 62–63
 partnership establishment,
 63–64
 preferred future, 64–65
 Rollnick and Zoffmann
 tools, 148

S

SDT. *See* Self-determination
 theory (SDT)
 Self-consciousness, 43–44

- Self-determination theory (SDT), 145
- Self-monitoring and reviewing progress, 164–165
- Self-monitoring of blood glucose (SMBG), 58
- Self-regulatory model, 138
- Sex, diabetes
- body issues, 79
 - common concerns, 74–75
 - consultation questions, 80–81
 - contraception choice, 75–76
 - diabetes impacts on, 74
 - factors influencing, 72–73
 - healthy pregnancies (see Pregnancy and diabetes)
 - hypoglycemia and sexual dysfunction, 80
 - passing it on risks, 76–77
 - prevalence, 72
 - risk-taking tips, 73
- Sexual dysfunction, 80
- SMBG. *See* Self-monitoring of blood glucose (SMBG)
- Smoking
- and diabetes, 85–86
 - European schools survey project, 85
 - prevention and cessation, 86–87
 - specific questions and advice, 87–88
- Social support, 161–162
- Solution-focused approach, 51
- Special groups and diabetes. *See* Diabetes and special groups
- Statins, 78
- Stepped care approach, 15–17
- Subclinical depression, 13
- T**
- T cell-mediated autoimmune destruction, 5
- Teratogenic drugs, 78–79
- Third National Health and Nutrition Examination Survey (NHANES III), 120
- Tobacco, 85
- Transtheoretical model, 152
- Treatment approaches, diabetes
- collaborative working practices development, 62–63
 - partnership establishment, 63–64
 - preferred future, 64–65
- Type 1 diabetes
- cannabis, 91
 - diagnosis, 5–6
 - DKA and control of diabetes, 89–90
 - ecstasy, 90
 - healthy pregnancies, 77
 - incidence and prevalence, 4
 - ketamine, 90
 - living with, 37–40
- Type 2 diabetes
- diagnosis of, 6–7
 - healthy pregnancies, 77–78
- V**
- Visual analogue scales, 109
- W**
- WHO. *See* World Health Organization (WHO)
- World Health Organization (WHO), 5, 69
- Y**
- Yorkshire register of diabetes in children and young adults study, 88